149 results about "Anti-coagulants" patented technology

An encased stent that discourages restenosis by having a homogenous endothelial cell lining along the inner wall of the stent. The endothelial cell lining may be coated on the stent before the stent is placed in the artery, or the endothelial cell lining may be grown after placement by several factors that encourage such growth and discourage restenosis. The endothelial cells to coat the stent may be genetically modified to enhance the growth of the endothelial cells into a homogeneous lining. The stent has a continuous lining in the form of a multi-layer polymer coating, including a conducting biocorrosion inhibiting layer and a continuous film of polyurethane coupled by a coupling agent to polyethylene glycol. Various drugs and cell factors may be incorporated into the lining, such as anti-thrombin, anti-inflammatory and anti-coagulant drugs, cell cycle inhibitors, and vascular endothelial growth factors.

A medically implantable stent comprising at least one piezo-electric material may be active, such as by one or more of: delivering an anti-coagulant or other therapeutic effect to a patient in which it is implanted; powering itself; and/or sending an outbound electronic signal to a remote device. When a stent can send such an outbound signal, a physician may non-invasively ascertain the condition of the tissue near the stent.

The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al.

Progesterone antagonists and SPRM are useful to prepare a medication for the treatment or the prophylaxis of excessive uterine bleeding in women with spontaneous or iatrogenic coagulation disorders such as thrombopenia, coagulation factor deficiency or anti-coagulant therapy. Treatment will last from 1 day to 180 days.

The present invention relates to a method of isolating and culturing mesenchymal stem cells using umbilical cord blood that is most ideal for cell therapy. The method comprises adding an anti-coagulant to umbilical cord blood having a volume of more than 45 ml per unit, which is obtained within 24 hours after parturition; diluting the resulting mixture of the anti-coagulant and umbilical cord blood with an αMEM (alpha-minimum essential medium), followed by centrifugation to harvest monocytes; and subjecting the obtained monocytes into suspension culture in the αMEM containing Stem Cell Factor, GM-CSF (granulocyte-macrophage colony-stimulating factor), G-CSF (granulocyte colony-stimulating factor), IL-3 (interleukin-3) and IL-6 (interleukin-6).

A method is provided for detecting filter clogging which are able to keep track of the filter clogging with precision and in detail. At least one pressure selected from the group consisting of a pressure Pa in a blood inflow portion (32a), a pressure Pv in a blood outflow portion (32b), a pressure Pf1 in a filtrate inflow portion (32c), and a pressure Pf2 in a filtrate outflow portion (32d) is measured continuously, then a variation (pressure waveform) of the pressure is analyzed, a clogging of a filter (32) is detected using the analyzed result. Thereby a clogging of a filter is detected early. As a result, it is possible to prevent from developing of the filter clogging by controlling a dosage amount of anti-coagulant properly and changing a flow rate of blood. The variation of the pressure wave may be analyzed by subjecting the variable to Fast Fourier Transform.

Methods and kits for treating a cardiac arrhythmia using a platelet rich plasma (PRP) composition are provided. Any type of arrhythmia may be treated using the PRP composition. The PRP composition may comprise PRP developed using blood collected from a patient suffering the cardiac arrhythmia. The PRP composition may be buffered to a physiological pH and may include one or more anti-arrhythmic agents, anti-coagulants, or other drugs. The PRP composition may be delivered using a nebulizer, minimally invasively, or surgically. In some embodiments, the PRP composition may be coated on one or more medical devices. The PRP composition may be delivered to an identified portion of the electrical conduction system of the heart affected and/or causing the arrhythmia to occur.

The present invention provides a composition of matter comprised of a mixture of two specific classes of compounds—Free-B-Ring flavonoids and flavans—referred to herein as UP736 for use in the prevention and treatment of diseases and conditions related to platelet aggregation and platelet-induced thrombosis. The invention further provides a novel composition of matter comprised of UP736 in combination with injectable or oral anticoagulants, antiplatelet agents, non-steroidal anti-inflammatory drugs (NSAIDs) and COX-2 selective inhibitors and a method for using said composition in the prevention and treatment of diseases and conditions related to platelet aggregation and platelet-induced thrombosis. Finally, this invention provides a method for using UP736 in combination with anti-platelet, anti-coagulant, prophylaxis agents and NSAIDs as a means for reducing the dosage of these agents, decreasing the side effects associated with acute or chronic administration of these agents; counteracting or antagonizing the risks of acute or chronic administration of these agents and for achieving additional and/or multiple clinical benefits.

There is described inter alia a device having a surface comprising a layered coating wherein the outer coating layer comprises a plurality of cationic hyperbranched polymer molecules characterized by having (i) a core moiety of molecular weight 14-1,000 Da (ii) a total molecular weight of 1,500 to 1,000,000 Da (iii) a ratio of total molecular weight to core moiety molecular weight of at least 80:1 and (iv) functional end groups, whereby one or more of said functional end groups have an anti-coagulant entity covalently attached thereto.

Implanted catheters are locked with a solution comprising a lower alcohol, typically ethanol, propanol, or butanol, in a range from 1% to 99% by volume, and an additive in a range from 1% to 99% by volume, the additive comprising an anti-microbial, typically taurolidine or triclosan, or an anti-coagulant, typically riboflavin, sodium citrate, ethylene diamine tetraacetic acid, or citric acid. The use of an alcohol and additive solution can effectively reduce fouling of the catheter, particularly clotting and thrombus in intravascular catheters, as well as eradicate existing infections and/or reduce the risk of potential infections. Existing infections and/or potential infections can be further reduced by employing a catheter body which permits an anti-microbial solution to penetrate into the catheter body and preferably through the catheter into tissue surrounding the implanted catheter.

An implantable human kidney replacement unit. Fully functional self contained, providing patients with end stage renal disease the freedom of traveling and moving about normally. Replacing donor kidneys. Implanted in the flank with at least one inlet and outlet tube each, sutured to the iliac artery and vain, at least one urine tube to the ureter. The housing constructed of anti-coagulant bacteriostatic materials has a plurality of reverse-osmosis process chambers with semipemeable membranes through the unit, followed by osmosis-diffusion chambers and membranes. Blood from the artery enters the first of the chambers. Small molecules such as water, magnesium, sodium, potassium, calcium, urea etc. are extracted from the blood according to their weight in atomic mass units as blood wipes past the self-cleaning membrane cartridges in the chambers. Molecules are further separated and urea sent to the bladder with excess water and electrolytes. The remainder is channeled to at least one diffusion chamber and reabsorbed into the blood. The same process is repeated in the other chambers where selected larger molecules such as creatinine and phosphorus are excreted, and some diffused back into the blood.

The present invention relates to a sampling tube for collecting and processing a whole blood sample. The sampling tube contains a reagent for differential hemolysis of whole blood, wherein said reagent for differential hemolysis comprises a chemical for differential hemolysis and an anti-coagulant, and wherein said sampling tube is a ready-to-use and single-use sampling tube. It also relates to the use of said sampling tube in the processing of a whole blood sample for liquid chromatography and also to the use of a blood sample processed in such sampling tube in a liquid chromatography-based analysis.

The invention discloses a preservative for preserving free DNA in peripheral blood. The preservative is composed of the following components in percentage by weight: 60 to 80% of ultrapure sterile water, 5 to 8% of anti-coagulant, 10 to 25% of antiseptic, 1 to 5% of metabolic inhibitor, and 0.5 to 3% of nuclease inhibitor. The provided preservative can preserve peripheral blood for at least 7 days at a normal temperature, 14 days at most, the blood can be transported at a normal temperature for 72 hours or more under the assistance of the preservative, 96 hours at most; and the free DNA amount is basically not affected during the period.

Activated protein C (APC), prodrug, and/or a variant thereof may be used as an inhibitor of apoptosis or cell death and/or a cell survival factor, especially for stressed or injured cells or tissues of the nervous system including subjects with neurode-generative disorders. Novel biological functions (e.g., neuroprotection) can be independent or separated from inhibition of clotting or inflammation, and other biological properties of APC (e.g., antithrombotic activity, ability to reduce NFκB-regulated gene expression). It can be used in the treatment of disease or other pathological conditions by at least inhibiting the p53-dependent and/or caspase-3-dependent pro-apoptotic signaling pathways in stressed or injured cells. Thus, APC, prodrugs, and variants thereof (e.g., APC protease domain mutants with reduced anti-coagulant activity) are prototypes of a class of agents for preventing apoptosis or cell death and/or promoting cell survival by direct action on brain cells. New protein C and/or APC variants with reduced anticoagulant activity may be selected thereby.

The present invention relates to an anti-microbial or anti-coagulating polymer resin and a method for preparing the same, and a medical appliance or instrument using the same, and more particularly to a method for preparing an anti-microbial or anti-coagulating medical polymer resin comprising the steps of simply mixing a polymer resin with at least one kind of pharmaceutically active material without using a solvent. The pharmaceutically active material is preferably an anti-microbial or anti-coagulant. According to the present invention, an anti-microbial or anti-coagulating material that is safe to a human body is mixed with a polymer resin by simple addition in an environmentally favorable non-solvent method, thereby maintaining superior anti-microbial effects even after high temperature molding, minimizing a released amount of anti-microbial to increase anti-microbial effect durability, and solving a toxic problem in a body. Therefore, the present invention can be extensively applied for medical appliances/instruments for a human body.

The invention relates to a medical instrument field, in particular to a medicine coating layer of blood vessel support of degradation polymer with anti-coagulant phosphoric acid choline ingredient. The medicine coating layer is formed by 1 percent to 50 percent medicine and medicine carrier of 50 percent to 99 percent degradation polymer with anti-coagulant phosphoric acid choline ingredient. The medicine can choose individual oxidation resisting medicine, mixture of diverse oxidation resisting medicines, mixture of single or diverse blood vessel restenosis medicines, mixture of single or diverse oxidation resisting medicine and blood vessel restenosis medicine composition. The medicine carrier is a copolymer of three macromolecules of polylactic acid (PDLLA), polyethylene glyco and phosphoric acid choline. And the medicine and medical biological degradation polymer are coated uniformly on the surface of the blood vessel support by the mixing or stratification coating method. According to local medication, the thrombus incidence rate can be effectively eased and reduced, so that the restenosis of coronary artery can be finally cured.

Aqueous blood-sample diluting reagent and method of its use for compelling a morphological change in a blood sample to yield an MCV value assayed at elapsed time after the sample is drawn to be consistent within a diagnostically acceptable range with the original, immediate post-drawing MCV value. Selection of a small amount of a predetermined surfactant added within a limited range of concentration, and of a salt for adjusting osmotic pressure of the sample is thereby determined. The blood sample is treated with an anti-coagulant agent immediately post-drawing, and for assay in a particle analyzer at post-drawing elapsed time is diluted with the reagent solution. The reagent has an osmotic pressure (pi) of approximately 150-400 mOsm/kg and a pH of 6.0-8.5. The surfactant is present in a 0.0005% to 0.5% concentration and has a hydrophile-lipophile balance (HLB) of 10-20.

Disclosed are devices for collecting and stabilizing blood or plasma and which contain an anti-coagulant, an antiplatelet agent, and a solubilization agent, and which may optionally include at least one other blood stabilization agent. Methods of making and using the devices in clinical medicine are also provided.

The invention relates to the use of N-desulfated heparin for treating or preventing inflammation, which is based on the experimental results in animal acute abdominal inflammation model and animal bleed model. The N-desulfated heparin's anti-inflammation activity is better than or equal to that of the low molecular weight heparin, and has low activity of anti-coagulant. From a series of N-desulfated heparin of different N-sulfur-containing, a sample of the best anti-inflammation activity and the lowest anti-coagulant activity was selected. The invention solved the problem of bleeding in the use of heparin for treating of inflammation, and provided a new pathway to use heparin to prevent and treat inflammation.

The invention is directed in part to a purified form of stabilized activated thrombin-activatable fibrinolysis inhibitor (TAFIa). The invention is further directed to a method of producing stabilized TAFIa. The invention is also directed to methods for therapeutic use of stabilized TAFIa such as in the treatment, prevention or management of diseases via an anti-coagulant effect. The invention is also directed to methods for therapeutic use of inhibitors of TAFIa such as in the treatment, prevention or management of diseases via a procoagulant effect. The invention is also directed to methods of diagnostic use of stabilized TAFIa such as a standard in a chromogenic or a fluorometric carboxypeptidase activity assay. The present invention is also directed to kits comprising stabilized TAFIa useful in measuring carboxypepetidase activity.

The invention discloses a preparation method of a hyperbranched polyimide anti-coagulant antibacterial material, and belongs to the field of chemical materials. The surface of amino-terminated hyperbranched polyimide is subjected to graft modification by 2-methacryloyloxyethyl phosphorylcholine to form a hyperbranched polyimide film, and the biocompatibility, anticoagulant property and antibacterial property of the prepared HBPI-MPC film are good.

The present invention provides methods for the production of N-deacetylate N-sulfate derivatives of non-sulfated N-acetyl heparosan (HS) polysaccharides, compounds thus obtained and compositions comprising same. This invention also provides applications of N-deacetylate N-sulfate derivatives of non-sulfated N-acetyl heparosan (HS) polysaccharides, and compositions comprising same, for use in controlling coagulation and treating thrombosis.